DK0933372T3 - Sulfonamidderivater som prodrugs for aspartylproteaseinhibitorer - Google Patents

Sulfonamidderivater som prodrugs for aspartylproteaseinhibitorer

Info

Publication number
DK0933372T3
DK0933372T3 DK98104292T DK98104292T DK0933372T3 DK 0933372 T3 DK0933372 T3 DK 0933372T3 DK 98104292 T DK98104292 T DK 98104292T DK 98104292 T DK98104292 T DK 98104292T DK 0933372 T3 DK0933372 T3 DK 0933372T3
Authority
DK
Denmark
Prior art keywords
prodrugs
protease inhibitors
sulfonamide derivatives
aspartyl protease
aspartyl
Prior art date
Application number
DK98104292T
Other languages
Danish (da)
English (en)
Inventor
Andrew Spaltenstein
Robert D Tung
Michael R Hale
Christopher T Baker
Eric Steven Furfine
Istvan Kaldor
Wieslaw Mieczyslaw Kazmierski
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25544691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0933372(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Application granted granted Critical
Publication of DK0933372T3 publication Critical patent/DK0933372T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65844—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a five-membered ring which may be condensed with another ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
DK98104292T 1997-12-24 1998-03-10 Sulfonamidderivater som prodrugs for aspartylproteaseinhibitorer DK0933372T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/998,050 US6436989B1 (en) 1997-12-24 1997-12-24 Prodrugs of aspartyl protease inhibitors

Publications (1)

Publication Number Publication Date
DK0933372T3 true DK0933372T3 (da) 2008-04-28

Family

ID=25544691

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98104292T DK0933372T3 (da) 1997-12-24 1998-03-10 Sulfonamidderivater som prodrugs for aspartylproteaseinhibitorer

Country Status (43)

Country Link
US (5) US6436989B1 (US06559137-20030506-C00153.png)
EP (2) EP1944300A3 (US06559137-20030506-C00153.png)
JP (3) JP3736964B2 (US06559137-20030506-C00153.png)
KR (1) KR100520737B1 (US06559137-20030506-C00153.png)
CN (2) CN100503589C (US06559137-20030506-C00153.png)
AP (1) AP1172A (US06559137-20030506-C00153.png)
AR (1) AR017965A1 (US06559137-20030506-C00153.png)
AT (1) ATE382042T1 (US06559137-20030506-C00153.png)
AU (1) AU755087B2 (US06559137-20030506-C00153.png)
BG (1) BG64869B1 (US06559137-20030506-C00153.png)
BR (1) BR9814480A (US06559137-20030506-C00153.png)
CA (1) CA2231700C (US06559137-20030506-C00153.png)
CO (1) CO4990992A1 (US06559137-20030506-C00153.png)
CZ (1) CZ301653B6 (US06559137-20030506-C00153.png)
DE (2) DE122008000021I2 (US06559137-20030506-C00153.png)
DK (1) DK0933372T3 (US06559137-20030506-C00153.png)
EA (1) EA003509B1 (US06559137-20030506-C00153.png)
EE (1) EE04466B1 (US06559137-20030506-C00153.png)
ES (1) ES2299193T3 (US06559137-20030506-C00153.png)
FR (1) FR08C0015I2 (US06559137-20030506-C00153.png)
HK (1) HK1021737A1 (US06559137-20030506-C00153.png)
HU (2) HU229596B1 (US06559137-20030506-C00153.png)
ID (1) ID24962A (US06559137-20030506-C00153.png)
IL (2) IL136941A0 (US06559137-20030506-C00153.png)
IS (1) IS2817B (US06559137-20030506-C00153.png)
LU (1) LU91426I2 (US06559137-20030506-C00153.png)
ME (1) MEP82008A (US06559137-20030506-C00153.png)
MY (1) MY131525A (US06559137-20030506-C00153.png)
NL (1) NL300339I2 (US06559137-20030506-C00153.png)
NO (2) NO326265B1 (US06559137-20030506-C00153.png)
NZ (1) NZ505776A (US06559137-20030506-C00153.png)
OA (1) OA11468A (US06559137-20030506-C00153.png)
PE (1) PE20000048A1 (US06559137-20030506-C00153.png)
PL (1) PL202845B1 (US06559137-20030506-C00153.png)
PT (1) PT933372E (US06559137-20030506-C00153.png)
RS (1) RS52483B (US06559137-20030506-C00153.png)
SI (1) SI0933372T1 (US06559137-20030506-C00153.png)
SK (1) SK287123B6 (US06559137-20030506-C00153.png)
TR (1) TR200002615T2 (US06559137-20030506-C00153.png)
TW (1) TW486474B (US06559137-20030506-C00153.png)
UA (1) UA72733C2 (US06559137-20030506-C00153.png)
WO (1) WO1999033815A1 (US06559137-20030506-C00153.png)
ZA (1) ZA9811830B (US06559137-20030506-C00153.png)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122000A1 (en) * 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
UA59384C2 (uk) * 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
EP1082120A1 (en) 1998-06-02 2001-03-14 OSI Pharmaceuticals, Inc. PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
AU6329599A (en) * 1998-09-28 2000-04-17 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
AU2002302363B2 (en) 2001-02-14 2008-05-01 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors
OA12464A (en) 2001-04-09 2006-05-24 Tibotec Pharm Ltd Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide HIV protease inhibitors.
PT1387842E (pt) 2001-05-11 2009-07-20 Tibotec Pharm Ltd 2-aminobenzoxazolsulfonamidas inibidoras de largo espectro da protease hiv
US7576084B2 (en) * 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
AU2002360436A1 (en) 2001-11-30 2003-06-17 Osi Pharmaceuticals, Inc. 2-aryl pyrrologpyrimidines for a1 and a3 receptors
AR037797A1 (es) * 2001-12-12 2004-12-01 Tibotec Pharm Ltd Combinacion de inhibidores de proteasa dependientes del citocromo p450
DE60236458D1 (de) 2001-12-20 2010-07-01 Osi Pharm Inc Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung
WO2003053366A2 (en) 2001-12-20 2003-07-03 Osi Pharmaceuticals, Inc. Pyrimidine a2b selective antagonist compounds, their synthesis and use
TWI336621B (en) 2001-12-21 2011-02-01 Tibotec Pharm Ltd Broad spectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors
MY142238A (en) 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
EP1501841A2 (en) 2002-04-26 2005-02-02 Gilead Sciences, Inc. Non nucleoside reverse transcriptase inhibitors
DE60315984T2 (de) 2002-05-17 2008-05-29 Tibotec Pharmaceuticals Ltd. Substituierte benzisoxazolsulfonamide mit breitbändiger hiv-protease hemmender wirkung
AU2003262574B2 (en) 2002-08-14 2009-07-09 Tibotec Pharmaceuticals Ltd. Broadspectrum substituted oxindole sulfonamide HIV protease inhibitors
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CA2425031A1 (en) * 2003-04-01 2004-10-01 Smithkline Beecham Corporation Pharmaceutical compositions
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
KR20060022647A (ko) 2003-04-25 2006-03-10 길리애드 사이언시즈, 인코포레이티드 키나아제 억제 포스포네이트 유사체
PT1628685E (pt) 2003-04-25 2011-03-16 Gilead Sciences Inc Análogos de fosfonatos antivirais
WO2004096285A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
JP4738333B2 (ja) * 2003-07-09 2011-08-03 パラテック ファーマシューティカルズ インコーポレイテッド ９−アミノメチルテトラサイクリン化合物のプロドラッグ
CN1845897A (zh) 2003-07-09 2006-10-11 帕拉特克药品公司 取代的四环素化合物
US20050119163A1 (en) 2003-09-18 2005-06-02 The Government Of The United States Of America, As Represented By The Secretary, SH2 domain binding inhibitors
WO2005044308A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
WO2005044279A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
US8193227B2 (en) 2003-12-11 2012-06-05 Abbott Laboratories HIV protease inhibiting compounds
US7834043B2 (en) * 2003-12-11 2010-11-16 Abbott Laboratories HIV protease inhibiting compounds
US20050131042A1 (en) * 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
MXPA06006730A (es) * 2003-12-15 2006-08-31 Schering Corp Inhibidores de aspartil proteasa heterociclicos.
JP4936897B2 (ja) 2003-12-18 2012-05-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗増殖剤としてのピリド−およびピリミドピリミジン誘導体
MXPA06006899A (es) 2003-12-22 2006-09-04 Gilead Sciences Inc Derivados de carbovir y abacavir 4'-sustituidos asi como compuestos relacionados con actividad antiviral de virus de inmunodeficiencia humana y virus de la hepatitis c.
NZ590128A (en) 2004-07-06 2012-08-31 Abbott Lab Prodrugs of HIV protease inhibitors
ME01945B (me) 2004-07-27 2011-12-31 Gilead Sciences Inc Nukleozid-fosfonatni konjugati kao sredstva protiv hiv-a
US7388008B2 (en) * 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
WO2006012725A1 (en) 2004-08-02 2006-02-09 Ambrilia Biopharma Inc. Lysine based compounds
EP1789030A2 (en) 2004-08-30 2007-05-30 Interstitial Therapeutics Medical implant provided with inhibitors of atp synthesis
WO2006058905A1 (en) 2004-12-01 2006-06-08 Devgen Nv 5-CARBOXAMIDO SUBSTITUTED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE Kv FAMILY
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
EP1941799A3 (en) 2004-12-17 2008-09-17 Devgen NV Nematicidal compositions
EP2161275A1 (en) * 2005-01-19 2010-03-10 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
WO2006104646A1 (en) * 2005-03-11 2006-10-05 Smithkline Beecham Corporation Hiv protease inhibitors
AR053845A1 (es) 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
CA2606025A1 (en) 2005-04-27 2006-11-02 Ambrilia Biopharma Inc. Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
US8003627B2 (en) 2005-10-21 2011-08-23 Universiteit Antwerpen Urokinase inhibitors
AR058238A1 (es) 2005-11-28 2008-01-23 Tibotec Pharm Ltd Compuestos y derivados de aminofenilsulfonamida sustituida como inhibidores de proteasa del vih
TWI385173B (zh) 2005-11-28 2013-02-11 Tibotec Pharm Ltd 作為ｈｉｖ蛋白酶抑制劑之經取代的胺基苯基磺醯胺化合物
PL1954718T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8227450B2 (en) * 2005-11-30 2012-07-24 Ambrilia Biopharma Inc. Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
RU2418804C2 (ru) * 2005-12-27 2011-05-20 Оцука Фармасьютикал Ко., Лтд. Водорастворимое соединение бензоазепина и содержащая его фармацевтическая композиция
JP2009542778A (ja) 2006-07-13 2009-12-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｍｔｋｉキナゾリン誘導体
AU2007294124A1 (en) 2006-09-08 2008-03-13 Bayer Schering Pharma Aktiengesellschaft Compounds and methods for 18F labeled agents
CA2664118A1 (en) * 2006-09-21 2008-07-03 Ambrilia Biopharma Inc. Protease inhibitors
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
KR101518079B1 (ko) 2007-03-12 2015-05-06 넥타르 테라퓨틱스 올리고머-프로테아제 억제제 컨주게이트
WO2009016132A1 (en) 2007-07-27 2009-02-05 Janssen Pharmaceutica Nv Pyrrolopyrimidines
EP2053033A1 (en) 2007-10-26 2009-04-29 Bayer Schering Pharma AG Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
WO2009112439A1 (en) 2008-03-10 2009-09-17 Janssen Pharmaceutica Nv 4-aryl-2-anilino-pyrimidines as plk kinase inhibitors
WO2009114151A1 (en) * 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-amino acid and olgomer-atazanavir conjugates
EP2116236A1 (en) 2008-04-21 2009-11-11 Université de Mons-Hainaut Bisbenzamidine derivatives for use as antioxidant
CN102089318B (zh) 2008-07-08 2014-05-21 吉里德科学公司 Hiv抑制剂化合物的盐
ES2623794T3 (es) 2008-12-09 2017-07-12 Gilead Sciences, Inc. Intermedios para la preparación de moduladores de receptores tipo toll
WO2010134045A1 (en) * 2009-05-20 2010-11-25 Ranbaxy Laboratories Limited Amorphous fosamprenavir calcium
EP2440249A2 (en) 2009-06-12 2012-04-18 Nektar Therapeutics Covalent conjugates comprising a protease inhibitor, a water-soluble, non-peptidic oligomer and a lipophilic moiety
EP2477996A1 (en) 2009-09-16 2012-07-25 Ranbaxy Laboratories Limited Process for the preparation of fosamprenavir calcium
WO2011061590A1 (en) 2009-11-17 2011-05-26 Hetero Research Foundation Novel carboxamide derivatives as hiv inhibitors
WO2011061295A1 (en) 2009-11-19 2011-05-26 Blue Medical Devices Bv Narrow profile composition-releasing expandable medical balloon catheter
US20110165202A1 (en) * 2010-01-07 2011-07-07 Pliva Hrvatska D.O.O. Solid state forms of fosamprenavir calcium salt and processes for preparation thereof
EA025176B1 (ru) 2010-01-27 2016-11-30 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
US20110224443A1 (en) * 2010-03-15 2011-09-15 Venkata Naga Brahmeshwara Rao Mandava Preparation of fosamprenavir calcium
WO2011114212A1 (en) 2010-03-19 2011-09-22 Lupin Limited Ammonium, calcium and tris salts of fosamprenavir
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2011141515A1 (en) 2010-05-14 2011-11-17 Bayer Pharma Aktiengesellschaft Diagnostic agents for amyloid beta imaging
WO2011158259A1 (en) 2010-06-18 2011-12-22 Matrix Laboratories Ltd Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts thereof
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
US8877947B2 (en) * 2010-09-10 2014-11-04 Lupin Limited Process for preparation of substantially pure fosamprenavir calcium and its intermediates
GB201019043D0 (en) 2010-11-10 2010-12-22 Protea Biopharma N V Use of 2',5'-oligoadenylate derivative compounds
WO2012085625A1 (en) 2010-12-21 2012-06-28 Lupin Limited Process for the preparation of fosamprenavir calcium and intermediate used in its preparation
WO2012107937A2 (en) * 2011-02-10 2012-08-16 Mylan Laboratories Ltd Crystalline fosamprenavir calcium and process for the preparation thereof"
CN112961855A (zh) 2011-06-21 2021-06-15 阿尔尼拉姆医药品有限公司 血管生成素样3(ANGPTL3)iRNA组合物及其使用方法
EP4134433A1 (en) 2011-06-23 2023-02-15 Alnylam Pharmaceuticals, Inc. Serpina1 sirnas: compositions of matter and methods of treatment
US9309213B2 (en) 2011-07-11 2016-04-12 Purdue Research Foundation C-3 substituted bicyclooctane based HIV protease inhibitors
WO2013011485A1 (en) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Process for the preparation of sulfonamides useful as retroviral protease inhibitors
US9233943B2 (en) 2012-01-10 2016-01-12 Council Of Scientific & Industrial Research Process for synthesis of syn azido epdxide and its use as intermediate for the synthesis of amprenavir and saquinavir
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
EP2700396A3 (en) 2012-06-20 2015-04-29 Sylphar Nv Strip for the delivery of oral care compositions
WO2014059034A2 (en) 2012-10-09 2014-04-17 President And Fellows Of Harvard College Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation
JP2015536940A (ja) 2012-10-29 2015-12-24 シプラ・リミテッド 抗ウイルス性ホスホネート類似体及びその製造方法
RS56783B9 (sr) 2012-12-05 2021-12-31 Alnylam Pharmaceuticals Inc Sastavi pcsk9 irnk i postupci njihovih primena
KR102234620B1 (ko) 2013-03-14 2021-04-05 알닐람 파마슈티칼스 인코포레이티드 보체 성분 Ｃ5 ｉＲＮＡ 조성물 및 그 이용 방법
EP3412774A1 (en) 2013-05-22 2018-12-12 Alnylam Pharmaceuticals, Inc. Serpina1 irna compositions and methods of use thereof
SG11201510565TA (en) 2013-05-22 2016-01-28 Alnylam Pharmaceuticals Inc Tmprss6 irna compositions and methods of use thereof
CN105814205B (zh) 2013-12-12 2019-11-19 阿尔尼拉姆医药品有限公司 补体成分iRNA组合物及其使用方法
EA201691587A1 (ru) 2014-02-11 2017-01-30 Элнилэм Фармасьютикалз, Инк. КОМПОЗИЦИИ НА ОСНОВЕ iRNA ДЛЯ КЕТОГЕКСОКИНАЗЫ (KHK) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2015175510A1 (en) 2014-05-12 2015-11-19 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating a serpinc1-associated disorder
CA3215908A1 (en) 2014-05-22 2015-11-26 Alnylam Pharmaceuticals, Inc. Angiotensinogen (agt) irna compositions and methods of use thereof
WO2016003450A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Pkc-epsilon inhibitors
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
US11116774B2 (en) 2014-07-11 2021-09-14 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of HIV
EP3191591A1 (en) 2014-09-12 2017-07-19 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
WO2016061487A1 (en) 2014-10-17 2016-04-21 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
US9738664B2 (en) 2014-10-29 2017-08-22 Wisconsin Alumni Research Foundation Boronic acid inhibitors of HIV protease
EP3904519A1 (en) 2014-10-30 2021-11-03 Genzyme Corporation Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
WO2016081444A1 (en) 2014-11-17 2016-05-26 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
WO2016083490A1 (en) 2014-11-27 2016-06-02 Remynd Nv Compounds for the treatment of amyloid-associated diseases
EP3256587A2 (en) 2015-02-13 2017-12-20 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
JP6975641B2 (ja) 2015-04-13 2021-12-01 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. アンギオポエチン様３（ＡＮＧＰＴＬ３）ｉＲＮＡ組成物およびそれらの使用方法
DK3288637T3 (da) 2015-04-28 2022-10-17 Newsouth Innovations Pty Ltd Målretning af nad+ til behandling af kemoterapi- og radioterapi-induceret, kognitiv funktionsnedsættelse, neuropatier og inaktivitet
CN108271386B (zh) 2015-05-06 2022-07-15 阿尔尼拉姆医药品有限公司 因子XII(哈格曼因子)(F12)、激肽释放酶B、血浆(夫列契因子)1(KLKB1)和激肽原1(KNG1)iRNA组合物及其使用方法
EP3310918B1 (en) 2015-06-18 2020-08-05 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
EP3350328A1 (en) 2015-09-14 2018-07-25 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
JP2018527366A (ja) 2015-09-15 2018-09-20 ギリアード サイエンシーズ， インコーポレイテッド ＨＩＶを処置するためのｔｏｌｌ様レセプターのモジュレーター
EP3386518A1 (en) 2015-12-07 2018-10-17 Genzyme Corporation Methods and compositions for treating a serpinc1-associated disorder
WO2017100542A1 (en) 2015-12-10 2017-06-15 Alnylam Pharmaceuticals, Inc. Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof
JP2019518028A (ja) 2016-06-10 2019-06-27 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 補体成分Ｃ５ｉＲＮＡ組成物及び発作性夜間血色素尿症（ＰＮＨ）を処置するためのその使用方法
TWI788312B (zh) 2016-11-23 2023-01-01 美商阿尼拉製藥公司 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
TWI790217B (zh) 2016-12-16 2023-01-21 美商阿尼拉製藥公司 使用甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物於治療或預防ＴＴＲ相關疾病之方法
EP3621963B1 (en) 2017-05-11 2024-01-24 Remynd N.V. Compounds for the treatment of epilepsy, neurodegenerative disorders and other cns disorders
CN117298114A (zh) 2017-07-21 2023-12-29 Viiv保健公司 用于治疗hib感染和aids的方案
US10851125B2 (en) 2017-08-01 2020-12-01 Gilead Sciences, Inc. Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate
SG11202002940QA (en) 2017-11-01 2020-04-29 Alnylam Pharmaceuticals Inc Complement component c3 irna compositions and methods of use thereof
KR20210043647A (ko) 2018-08-13 2021-04-21 알닐람 파마슈티칼스 인코포레이티드 B형 간염 바이러스 (HBV) dsRNA 제제 조성물 및 이의 사용 방법
WO2020150431A1 (en) 2019-01-16 2020-07-23 Genzyme Corporation Serpinc1 irna compositions and methods of use thereof
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
CN115175909A (zh) 2020-02-24 2022-10-11 鲁汶天主教大学 吡咯并吡啶和咪唑并吡啶抗病毒化合物
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
JP2024500543A (ja) 2020-12-22 2024-01-09 ルクセンブルク インスティテュート オブ ヘルス（エルアイエイチ） がん及び循環器疾患の処置のための選択的ａｃｋｒ３調節物質としてのコノリジンアナログ
WO2022184898A1 (en) 2021-03-04 2022-09-09 Universiteit Antwerpen Quinazolin-4-one and thieno[2,3-d]pyrimidin-4-one inhibitors of erbb4 (her4) for use in the treatment of cancer
CA3217589A1 (en) 2021-05-31 2022-12-08 Frederik Giesel Improved prostate-specific membrane antigen targeting radiopharmaceuticals and uses thereof
WO2023021132A1 (en) 2021-08-18 2023-02-23 Katholieke Universiteit Leuven 6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues
WO2023046900A1 (en) 2021-09-23 2023-03-30 Katholieke Universiteit Leuven Ribonucleoside analogues against -sars-cov-2
WO2023241799A1 (en) 2022-06-15 2023-12-21 Université Libre de Bruxelles Flavanols for use in the treatment of retroviral infections
WO2024062043A1 (en) 2022-09-21 2024-03-28 Universiteit Antwerpen Substituted phenothiazines as ferroptosis inhibitors

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3743722A (en) 1971-07-14 1973-07-03 Abbott Lab Anti-coagulant isolation
FR2459235A1 (fr) 1979-06-14 1981-01-09 Sanofi Sa Nouveaux derives de sulfonyl-aniline, leur procede de preparation et leur application therapeutique
JPS5946252A (ja) 1982-09-09 1984-03-15 Dainippon Ink & Chem Inc 含フツ素アミノカルボキシレ−トおよびその製法
JPS5948449A (ja) 1982-09-13 1984-03-19 Dainippon Ink & Chem Inc 直鎖状含フツ素アニオン化合物およびその製造方法
JPS6171830A (ja) 1984-09-17 1986-04-12 Dainippon Ink & Chem Inc 界面活性剤組成物
US4616088A (en) 1984-10-29 1986-10-07 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitor
US4629724A (en) 1984-12-03 1986-12-16 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitors
DE3635907A1 (de) 1986-10-22 1988-04-28 Merck Patent Gmbh Hydroxy-aminosaeurederivate
GB2200115B (en) 1987-01-21 1990-11-14 Sandoz Ltd Novel peptide derivatives, their production and use
CA1340588C (en) 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
IL91780A (en) 1988-10-04 1995-08-31 Abbott Lab History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them
WO1990007330A1 (en) 1989-01-06 1990-07-12 The Regents Of The University Of California Selection method for specific useful pharmaceutical compounds
US5151438A (en) 1989-05-23 1992-09-29 Abbott Laboratories Retroviral protease inhibiting compounds
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
IE902295A1 (en) 1989-07-07 1991-01-16 Abbott Lab Amino acid analog cck antagonists
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
JPH07502970A (ja) 1990-06-01 1995-03-30 ザ・デュポン・メルク・ファーマシュウティカル・カンパニー １，４―ジアミノ―２，３―ジヒドロキシブタン類
TW225540B (US06559137-20030506-C00153.png) 1990-06-28 1994-06-21 Shionogi & Co
JPH06505963A (ja) 1990-11-19 1994-07-07 モンサント　カンパニー レトロウイルスプロテアーゼ阻害剤
DK0558657T3 (da) 1990-11-19 1997-07-07 Monsanto Co Retrovirale proteaseinhibitorer
DK0558673T3 (da) 1990-11-19 1996-07-29 Monsanto Co Retrovirale proteaseinhibitorer
CA2096408C (en) 1990-11-19 2005-02-08 Gary Anthony Decrescenzo Retroviral protease inhibitors
IE20010533A1 (en) 1990-11-20 2003-03-05 Abbott Lab Intermediates for preparing retroviral protease inhibiting compounds
ES2112880T3 (es) 1991-11-08 1998-04-16 Merck & Co Inc Inhibidores de la proteasa de vih utiles para el tratamiento del sida.
CA2131182C (en) 1992-05-20 2005-04-26 John S. Ng Method for making intermediates useful in synthesis of retroviral protease inhibitors
ES2155069T3 (es) 1992-05-21 2001-05-01 Monsanto Co Inhibidores de proteasas retrovirales.
KR100336699B1 (ko) 1992-08-25 2002-05-13 윌리암스 로저 에이 레트로바이러스 프로테아제 저해제로서 유용한히드록시에틸아미노 술폰아미드
US5521219A (en) 1992-08-25 1996-05-28 G. D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
CA2142998C (en) 1992-08-25 2008-01-29 Michael L. Vazquez N-(alkanoylamino-2-hydroxypropyl)-sulfonamides useful as retroviral protease inhibitors
SK65094A3 (en) * 1992-09-03 1995-03-08 Boehringer Ingelheim Kg Aminoacid derivatives, process for producing the same and pharmaceutical compositions containing these derivatives
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5783701A (en) 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
TW372972B (en) 1992-10-23 1999-11-01 Novartis Ag Antiretroviral acyl compounds
ES2134924T3 (es) 1992-10-30 1999-10-16 Searle & Co Acidos sulfonilalcanoilamino-hidroxietilamino-sulfamicos utiles como inhibidores de proteasas retrovirales.
US6156768A (en) 1992-10-30 2000-12-05 G. D. Searle & Co. Alpha- and beta-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
WO1994018192A1 (en) 1993-02-12 1994-08-18 Merck & Co., Inc. Piperazine derivatives as hiv protease inhibitors
TW281669B (US06559137-20030506-C00153.png) 1993-02-17 1996-07-21 Chugai Pharmaceutical Co Ltd
DK0715618T3 (da) 1993-08-24 1999-08-23 Searle & Co Hydroxyethylaminosulfonamider til anvendelse som inhibitorer af retrovirale proteaser
IL110898A0 (en) 1993-09-10 1994-11-28 Narhex Australia Pty Ltd Polar-substituted hydrocarbons
IL111584A0 (en) 1993-11-18 1995-01-24 Merck & Co Inc Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
US5527829A (en) 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
DE19506742A1 (de) 1995-02-27 1996-08-29 Bayer Ag Verwendung von Chinoxalinen in Kombination mit Protease-Inhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen
US5691372A (en) 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US5750493A (en) 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
US5646180A (en) 1995-12-05 1997-07-08 Vertex Pharmaceuticals Incorporated Treatment of the CNS effects of HIV
US6180634B1 (en) 1997-11-13 2001-01-30 Merck & Co., Inc. Combination therapy for the treatment of AIDS
EE200000386A (et) * 1997-12-24 2001-12-17 Vertex Pharmaceuticals Incorporated Aspartüülproteaasi inhibiitorite eelravimid
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
CO5261510A1 (es) * 1999-02-12 2003-03-31 Vertex Pharma Inhibidores de aspartil proteasa

Also Published As

Publication number Publication date
EP1944300A2 (en) 2008-07-16
NO326265B1 (no) 2008-10-27
ES2299193T3 (es) 2008-05-16
LU91426I2 (fr) 2008-06-02
US20100124543A1 (en) 2010-05-20
DE69838903T2 (de) 2008-09-18
TW486474B (en) 2002-05-11
JPH11209337A (ja) 1999-08-03
IL136941A (en) 2006-06-11
NO2009008I2 (US06559137-20030506-C00153.png) 2010-09-27
FR08C0015I2 (fr) 2009-10-30
BR9814480A (pt) 2001-09-25
JP3736964B2 (ja) 2006-01-18
BG104631A (en) 2001-02-28
YU39800A (sh) 2004-03-12
PT933372E (pt) 2008-03-31
SK287123B6 (sk) 2009-12-07
HUS1400042I1 (hu) 2017-06-28
PE20000048A1 (es) 2000-02-08
IL136941A0 (en) 2001-06-14
EE04466B1 (et) 2005-04-15
AR017965A1 (es) 2001-10-24
LU91426I9 (US06559137-20030506-C00153.png) 2018-12-28
ID24962A (id) 2000-08-31
US6436989B1 (en) 2002-08-20
EA003509B1 (ru) 2003-06-26
ME00561B (me) 2011-10-10
PL202845B1 (pl) 2009-07-31
CO4990992A1 (es) 2000-12-26
DE122008000021I2 (de) 2010-02-04
KR20010033600A (ko) 2001-04-25
IS2817B (is) 2012-11-15
CN1284071A (zh) 2001-02-14
EA200000703A1 (ru) 2000-12-25
NO2009008I1 (US06559137-20030506-C00153.png) 2009-05-04
SI0933372T1 (sl) 2008-06-30
BG64869B1 (bg) 2006-07-31
PL342113A1 (en) 2001-05-21
HUP0101831A3 (en) 2002-08-28
HUP0101831A2 (hu) 2002-04-29
US20050148548A1 (en) 2005-07-07
ATE382042T1 (de) 2008-01-15
NZ505776A (en) 2003-06-30
JP2009102400A (ja) 2009-05-14
EP0933372A1 (en) 1999-08-04
MEP82008A (en) 2011-12-20
SK9662000A3 (en) 2001-02-12
US20030207871A1 (en) 2003-11-06
CA2231700C (en) 2005-08-09
JP4282639B2 (ja) 2009-06-24
FR08C0015I1 (US06559137-20030506-C00153.png) 2008-05-30
IS5546A (is) 2000-06-22
AP1172A (en) 2003-06-30
CZ301653B6 (cs) 2010-05-12
AU6546698A (en) 1999-07-19
EE200000385A (et) 2001-12-17
US6559137B1 (en) 2003-05-06
AP2000001850A0 (en) 2000-06-30
CA2231700A1 (en) 1999-06-24
DE122008000021I1 (de) 2008-08-14
US6838474B2 (en) 2005-01-04
RS52483B (en) 2013-02-28
DE69838903D1 (de) 2008-02-07
NO20003304L (no) 2000-08-21
US7592368B2 (en) 2009-09-22
ZA9811830B (en) 2000-06-23
EP0933372B1 (en) 2007-12-26
CN100503589C (zh) 2009-06-24
NL300339I2 (nl) 2009-11-02
NL300339I1 (nl) 2008-06-02
TR200002615T2 (tr) 2001-01-22
HK1021737A1 (en) 2000-06-30
JP2005350478A (ja) 2005-12-22
CZ20002363A3 (cs) 2000-11-15
KR100520737B1 (ko) 2005-10-12
EP1944300A3 (en) 2008-11-05
WO1999033815A1 (en) 1999-07-08
NO20003304D0 (no) 2000-06-23
UA72733C2 (en) 2005-04-15
AU755087B2 (en) 2002-12-05
OA11468A (en) 2004-05-05
HU229596B1 (en) 2014-02-28
MY131525A (en) 2007-08-30
CN101565412A (zh) 2009-10-28

Similar Documents

Publication Publication Date Title
DK0933372T3 (da) Sulfonamidderivater som prodrugs for aspartylproteaseinhibitorer
NO20006405D0 (no) Sulfonamidinhibitorer for aspartylprotease
EE9700266A (et) Aspartüüli proteaasi THF-i sisaldavad sulfoonamiidinhibiitorid
EE200000386A (et) Aspartüülproteaasi inhibiitorite eelravimid
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
NO20014483L (no) Aminderivater som proteaseinhibitorer
NO992821D0 (no) Ketobenzamider som calpain-inhibitorer
NO986090D0 (no) Fenylalaninderivater som integrininhibitorer
NO993587L (no) Sulfonamid-metalloprotease-inhibitorer
NO20004696L (no) Kinoloner som serinproteaseinhibitorer
NO20010686D0 (no) Hydroksypipecolathydroksaminsyrederivater som MMP inhibitorer
NO992725L (no) 6-Fenylpyridyl-2-amin-derivater anvendelige som NOS-inhibitorer
DK1383731T3 (da) Biarylforbindelser som serinproteaseinhibitorer
NO985874D0 (no) Bestemte fosfinylderivater nyttige som naaladase inhibitorer
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
NO20012980D0 (no) Proteaseinhibitorer
NO20030867L (no) Hydroksamderivater anvendelig som deacetylaseinhibitorer
NO980467D0 (no) 4-mercaptopyrrolidin-derivater som farnesyl-transerase-inhibitorer
ATE534622T1 (de) Aspartylprotease-inhibitoren
DK1222192T3 (da) Hexahydrofuro-2,3-b furan-3-yl-N-3-(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino-1-benzyl-2-hydroxypropyl-carbamat som retroviral proteaseinhibitor
NO20000957D0 (no) Forgrenede alkoksy-substituerte 2-aminopyridiner som NOS inhibitorer
NO991994D0 (no) Substituerte 4-bifenyl-4-hydroksysm°rsyrederivater som matriks-metalloproteaseinhibitorer
NO20011654L (no) Benzamidderivater som trombininhibitorer
NO20000094L (no) 6-Azaurcilderivater som IL-5 inhibitorer